Advances in proteomic prostate cancer biomarker discovery

Journal of Proteomics

Volumn 73, Issue 10, 2010, Pages 1839-1850

  Goo, Young Ah ^a   Goodlett, David R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

Biomarker; Prostate cancer; Proteomics; Systems biology

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER SCREENING; GENE SEQUENCE; HUMAN; METABOLOMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE FLUID; PROTEIN SECRETION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; URINALYSIS;

HUMANS; MALE; METABOLOMICS; NEOPLASM PROTEINS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956417496     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.04.002     Document Type: Review

References (88)

1. Waltregny D., Castronovo V. Recent advances in prostate cancer metastasis. Tumori 1996, 82:193-204.
2. Garnick M.B. The dilemmas of prostate cancer. Sci Am 1994, 270:72-81.
3. Kolonel L.N., Hankin J.H., Whittemore A.S., Wu A.H., Gallagher R.P., Wilkens L.R., et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000, 9:795-804.
4. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008, 8:268-278.
5. Shariat S.F., Karam J.A., Walz J., Roehrborn C.G., Montorsi F., Margulis V., et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008, 14:3785-3791.
6. Huggins C., Hodges C.V. Studies on prostatic cancer: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-297.
7. Javidan J., Deitch AD Shi X.B., de Vere White R.W. The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest 2005, 23:520-528.
8. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
9. Matharoo-Ball B., Ball G., Rees R. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches-a prostate cancer perspective. Vaccine 2007, 25(Suppl 2):B110-B121.
10. Parekh D.J., Ankerst D.P., Troyer D., Srivastava S., Thompson I.M. Biomarkers for prostate cancer detection. J Urol 2007, 178:2252-2259.
11. Schiffer E. Biomarkers for prostate cancer. World J Urol 2007, 25:557-562.
12. Fradet Y. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 2009, 19:243-246.
13. Hood B.L., Malehorn D.E., Conrads T.P., Bigbee W.L. Serum proteomics using mass spectrometry. Methods Mol Biol 2009, 520:107-128.
14. Vaezzadeh A.R., Steen H., Freeman M.R., Lee R.S. Proteomics and opportunities for clinical translation in urological disease. J Urol 2009, 182:835-843.
15. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
16. Adam B.L., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002, 62:3609-3614.
17. Qu Y., Adam B.L., Yasui Y., Ward M.D., Cazares L.H., Schellhammer P.F., et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002, 48:1835-1843.
18. Semmes O.J., Feng Z., Adam B.L., Banez L.L., Bigbee W.L., Campos D., et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005, 51:102-112.
19. McLerran D., Grizzle W.E., Feng Z., Bigbee W.L., Banez L.L., Cazares L.H., et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008, 54:44-52.
20. McLerran D., Grizzle W.E., Feng Z., Thompson I.M., Bigbee W.L., Cazares L.H., et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008, 54:53-60.
21. Rosenzweig C.N., Zhang Z., Sun X., Sokoll L.J., Osborne K., Partin A.W., et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol 2009, 181:1407-1414.
22. Byrne J.C., Downes M.R., O'Donoghue N., O'Keane C., O'Neill A., Fan Y., et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009, 8:942-957.
23. Qingyi Z., Lin Y., Junhong W., Jian S., Weizhou H., Long M., et al. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach. Cancer Invest 2009, 27:794-801.
24. Adachi J., Kumar C., Zhang Y., Olsen J.V., Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006, 7:R80.
25. M'Koma A.E., Blum D.L., Norris J.L., Koyama T., Billheimer D., Motley S., et al. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun 2007, 353:829-834.
26. Theodorescu D., Wittke S., Ross M.M., Walden M., Conaway M., Just I., et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006, 7:230-240.
27. Theodorescu D., Fliser D., Wittke S., Mischak H., Krebs R., Walden M., et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005, 26:2797-2808.
28. Moini M. Capillary electrophoresis mass spectrometry and its application to the analysis of biological mixtures. Anal Bioanal Chem 2002, 373:466-480.
29. Kaiser T., Wittke S., Just I., Krebs R., Bartel S., Fliser D., et al. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis 2004, 25:2044-2055.
30. Rehman I., Azzouzi A.R., Catto J.W., Allen S., Cross S.S., Feeley K., et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004, 64:1238-1243.
31. Hassan M.I., Kumar V., Kashav T., Alam N., Singh T.P., Yadav S. Proteomic approach for purification of seminal plasma proteins involved in tumor proliferation. J Sep Sci 2007, 30:1979-1988.
32. Okamoto A., Yamamoto H., Imai A., Hatakeyama S., Iwabuchi I., Yoneyama T., et al. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions. Oncol Rep 2009, 21:73-79.
33. Drake R.R., White K.Y., Fuller T.W., Igwe E., Clements M.A., Nyalwidhe J.O., et al. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics 2009, 72:907-917.
34. Burden H.P., Holmes C.H., Persad R., Whittington K. Prostasomes-their effects on human male reproduction and fertility. Hum Reprod Update 2006, 12:283-292.
35. Utleg A.G., Yi E.C., Xie T., Shannon P., White J.T., Goodlett D.R., et al. Proteomic analysis of human prostasomes. Prostate 2003, 56:150-161.
36. Poliakov A., Spilman M., Dokland T., Amling C.L., Mobley J.A. Structural heterogeneity and protein composition of exosome-like vesicles (prostasomes) in human semen. Prostate 2009, 69:159-167.
37. Pascal L.E., True L.D., Campbell D.S., Deutsch E.W., Risk M., Coleman I.M., et al. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 2008, 9:246.
38. Goo Y.A., Liu A.Y., Ryu S., Shaffer S.A., Malmstrom L., Page L., et al. Identification of secreted glycoproteins of human prostate and bladder stromal cells by comparative quantitative proteomics. Prostate 2009, 69:49-61.
39. Gillespie J.W., Gannot G., Tangrea M.A., Ahram M., Best C.J., Bichsel V.E., et al. Molecular profiling of cancer. Toxicol Pathol 2004, 32(Suppl 1):67-71.
40. Diaz JI Cazares L.H., Corica A., John Semmes O. Selective capture of prostatic basal cells and secretory epithelial cells for proteomic and genomic analysis. Urol Oncol 2004, 22:329-336.
41. Ahram M., Flaig M.J., Gillespie J.W., Duray P.H., Linehan W.M., Ornstein D.K., et al. Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 2003, 3:413-421.
42. Paweletz C.P., Liotta L.A., Petricoin E.F. New technologies for biomarker analysis of prostate cancer progression: laser capture microdissection and tissue proteomics. Urology 2001, 57:160-163.
43. Zheng Y., Xu Y., Ye B., Lei J., Weinstein M.H., O'Leary M.P., et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 2003, 98:2576-2582.
44. Sardana G., Jung K., Stephan C., Diamandis E.P. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008, 7:3329-3338.
45. Martin D.B., Gifford D.R., Wright M.E., Keller A., Yi E., Goodlett D.R., et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004, 64:347-355.
46. Vliegenthart J.F., Casset F. Novel forms of protein glycosylation. Curr Opin Struct Biol 1998, 8:565-571.
47. Roth J. Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions. Chem Rev 2002, 102:285-303.
48. Pommier S.J., Quan G.G., Christante D., Muller P., Newell A.E., Olson S.B., Diggs B., Muldoon L., Neuwelt E., Pommier R.F. Characterizing the HER2/neu Status and Metastatic Potential of Breast Cancer Stem/Progenitor Cells. Ann Surg Oncol 2009.
49. Benjapibal M., Neungton C. Pre-operative prediction of serum CA125 level in women with ovarian masses. Med Assoc Thai 2007, 90:1986-1991.
50. Benjapibal M., Neungton C. Pre-operative prediction of serum CA125 level in women with ovarian masses. J Med Assoc Thai 2007, 90:1986-1991.
51. Durand G., Seta N. Protein glycosylation and diseases: blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. Clin Chem 2000, 46:795-805.
52. Spiro R.G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002, 12:43R-56R.
53. Liu A.Y., Zhang H., Sorensen C.M., Diamond D.L. Analysis of prostate cancer by proteomics using tissue specimens. J Urol 2005, 173:73-78.
54. Drake R.R., Schwegler E.E., Malik G., Diaz J., Block T., Mehta A., et al. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics 2006, 5:1957-1967.
55. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17:994-999.
56. Hardt M., Witkowska H.E., Webb S., Thomas L.R., Dixon S.E., Hall S.C., et al. Assessing the effects of diurnal variation on the composition of human parotid saliva: quantitative analysis of native peptides using iTRAQ reagents. Anal Chem 2005, 77:4947-4954. 44.
57. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
58. Kuhn E., Wu J., Karl J., Liao H., Zolg W., Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004, 4:1175-1186.
59. Goo Y.A., Li Z., Pajkovic N., Shaffer S., Taylor G., Chen J.Z., et al. Systematic investigation of lycopene effects in LNCaP cells by use of novel large-scale proteomic analysis software. Proteomics Clinical Applications 2007, 1:513-523.
60. Hara T., Honda K., Shitashige M., Ono M., Matsuyama H., Naito K., et al. Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. Mol Cell Proteomics 2007, 6:479-491.
61. Meehan K.L., Sadar M.D. Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics 2004, 4:1116-1134.
62. Glen A., Gan C.S., Hamdy F.C., Eaton C.L., Cross S.S., Catto J.W., et al. iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res 2008, 7:897-907.
63. Garbis S.D., Tyritzis S.I., Roumeliotis T., Zerefos P., Giannopoulou E.G., Vlahou A., et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008, 7:3146-3158.
64. Thompson A., Schafer J., Kuhn K., Kienle S., Schwarz J., Schmidt G., et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 2003, 75:1895-1904.
65. Everley P.A., Krijgsveld J., Zetter B.R., Gygi S.P. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics 2004, 3:729-735.
66. Wang W., Zhou H., Lin H., Roy S., Shaler T.A., Hill L.R., et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal Chem 2003, 75:4818-4826.
67. Radulovic D., Jelveh S., Ryu S., Hamilton T.G., Foss E., Mao Y., et al. Informatics platform for global proteomic profiling and biomarker discovery using liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2004, 3:984-997.
68. Ryu S., Gallis B., Goo Y.A., Shaffer S.A., Radulovic D., Goodlett D.R. Comparison of a label-free quantitative proteomic method based on peptide ion current area to the isotope coded affinity tag method. Cancer Inform 2008, 6:243-255.
69. Liu H., Sadygov R.G., Yates J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004, 76:4193-4201.
70. Old W.M., Meyer-Arendt K., Aveline-Wolf L., Pierce K.G., Mendoza A., Sevinsky J.R., et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005, 4:1487-1502.
71. Colinge J., Chiappe D., Lagache S., Moniatte M., Bougueleret L. Differential proteomics via probabilistic peptide identification scores. Anal Chem 2005, 77:596-606.
72. Xu D., Suenaga N., Edelmann M.J., Fridman R., Muschel R.J., Kessler B.M. Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach. Mol Cell Proteomics 2008, 7:2215-2228.
73. Fortin T., Salvador A., Charrier J.P., Lenz C., Lacoux X., Morla A., et al. Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics 2009, 8:1006-1015.
74. Salameh W.A., Redor-Goldman M.M., Clarke N.J., Reitz R.E., Caulfield M.P. Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: total and free testosterone reference ranges. Steroids 2009.
75. Abate-Shen C., Shen M.M. Diagnostics: the prostate-cancer metabolome. Nature News and Views 2009, 457:799-800.
76. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
77. Ideker T., Galitski T., Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001, 2:343-372.
78. Lawlor K., Nazarian A., Lacomis L., Tempst P., Villanueva J. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Res 2009, 8:1489-1503.
79. Vellaichamy A., Sreekumar A., Strahler J.R., Rajendiran T., Yu J., Varambally S., et al. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS One 2009, 4:e7075.
80. LaBaer J., Ramachandran N. Protein microarrays as tools for functional proteomics. Curr Opin Chem Biol 2005, 9:14-19.
81. Fasolo J., Snyder M. Protein microarrays. Methods Mol Biol 2009, 548:209-222.
82. Wu C.C., MacCoss M.J., Howell K.E., Yates J.R. A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol 2003, 21:532-538.
83. Semmes O.J., Malik G., Ward M. Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. J Cell Biochem 2006, 98:496-503.
84. Siuti N., Kelleher N.L. Decoding protein modifications using top-down mass spectrometry. Nat Methods 2007, 4:817-821.
85. Tsai Y.S., Scherl A., Shaw J.L., MacKay C.L., Shaffer S.A., Langridge-Smith P.R., et al. Precursor ion independent algorithm for top-down shotgun proteomics. J Am Soc Mass Spectrom 2009, 20:2154-2166.
86. Panchaud A., Scherl A., Shaffer S.A., von Haller P.D., Kulasekara H.D., Miller S.I., Goodlett D.R. Precursor acquisition independent from ion count: how to dive deeper into the proteomics ocean. Anal Chem 2009.
87. Auffray C., Chen Z., Hood L. Systems medicine: the future of medical genomics and healthcare. Genome Med 2009, 1:2.
88. Aebersold R., Auffray C., Baney E., Barillot E., Brazma A., Brett C., et al. Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol Oncol 2009, 3:9-17.